NantKwest announces durable complete responses in Phase I aNK cell trial
NantKwest announced the final results of a phase I clinical trial of the company's aNK cell therapy platform in relapsed hematological malignancies. The data, published in the journal Oncotarget, demonstrated continuing evidence of safety and efficacy, with an overall response rate of 42% and no evidence of grade 3 or 4 adverse events from the infusions. Of note 2 out of the 12 patients in the safety study with relapsed Hodgkin's Lymphoma and Multiple Myeloma, demonstrated durable complete response with single agent aNK therapy, and remain free of disease to date, 10 years and 2 years respectively. Chairman and CEO Patrick Soon-Shiong said, "Consistent with previous studies, Dr. Keating's clinical trial results, reporting a 42% overall response rate, provide additional clinical validation of the unique potential to deliver long-term remissions with limited toxicity using the company's novel NK cell therapy. Our aNK cell therapy is currently in an ongoing Phase II clinical study in Merkel cell carcinoma and represent a critical, foundational component in the company's recently launched NANT Cancer Vaccine clinical trial program."